Abstract
Background:
Multiple Sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system. Although psoriasis and psoriasiform dermatitis are reported in MS patients, the prevalence of the diseases is uncertain globally and unstudied in Australia. This study aims to determine the frequency of psoriasis in a clinic-based cohort of Australian MS patients.
Methods:
A survey was conducted on 204 consecutive MS patients aged 18 and over who attended a tertiary MS clinic in Northern Sydney from July 2018 to December 2022.
Results:
A total of 204 patients were examined, comprising 137 female (67.2%) and 67 male (32.8%). The mean age was 48.8 years (SD = 13.6). Psoriasis was identified in 13.7% (28/204; 95% CI: 9.63% to 19.20%).
Discussion:
The frequency of psoriasis in MS is high and may be underestimated, given that many more patients have symptoms without signs. This implies an immunopathological link between the two conditions and is worthy of further study.
Introduction
Multiple Sclerosis (MS) is an immune-mediated, demyelinating disease of the central nervous system (1, 2). Although recent work and clinical data imply an increasing role for B-lymphocytes in the pathogenesis of MS, aberrant T-lymphocyte responses are likely necessary for the development of the disease and have been demonstrated among patients (3–5). Further, experimental models utilize myelin-specific T-lymphocytes (6, 7) to induce macrophage mediated, inflammatory demyelination and these changes recapitulate many elements of the human disease. To add complexity, the precise immunopathological mechanisms in individual MS patients may vary given the clinical and radiological heterogeneity of the disease, variance in the clinical course of MS and response to treatment (5, 8, 9).
Psoriasis (Pso) is a chronic, systemic T cell-mediated inflammatory condition of the skin and joints occurring in approximately 0.2–2% of the world population and notably more frequent in Caucasians (10). Pso is characterized by irritating or painful erythematous patches or plaques with silvery scales (10, 11). Like MS, the pathogenesis of Pso is determined by a genetic predisposition modulated by environmental triggers. Due to the fact this is a systemic inflammatory process, Pso patients are at higher risk of developing cardiovascular disease (12), cerebral vascular ischemia (13), chronic kidney disease (14), and uveitis (15). Given this wide range of associated co-morbidities, Pso has a significant negative physical and psychological impact on quality of life (16) and in severe Pso, shortened life expectancy (17, 18).
Like other immune-mediated conditions, MS patients exhibit a higher personal and familial rate of other autoimmune diseases (19). One case-control study in the US showed that Pso was the second most common co-existing autoimmune disease in MS patients after Hashimoto thyroiditis (20) but the association between Pso and MS is inconsistent with wide variance in reported incidence and prevalence (21, 22). The observed correlation between MS and Pso may be driven by shared genetic susceptibility (HLA alleles) as well as overlapping immunological pathways, particularly the IL-23/IL-17 axis and the generation of pro-inflammatory cytokines (IL-17 and TNF-α) (23, 24).
The current prevalence of Pso in patients with MS in Australia is unknown. We sought to determine the accurate frequency of Pso among patients with MS using a focused questionnaire in a prospective, clinic-based study in Sydney.
Materials and methods
The study was conducted using a survey with 29 directed questions (Appendix 1) either distributed via email or performed face-to-face on MS patients aged 18 years and over attending a large MS specialist outpatient clinic at Royal North Shore Hospital (RNSH), Sydney, from July 2018 to December 2022, which supports 1142 patients. Two hundred and four consecutive MS patients were randomly selected and invited to participate. All participating patients provided their consent.
The study was approved by the Northern Sydney Local Health District Human Research Ethics Committee, which is constituted in accordance with the National Statement on Ethical Conduct in Human Research, 2007 (NHMRC; 2021/ETH00892).
In an interview setting, patients completed a questionnaire which aimed to determine the incidence and prevalence of Pso and to understand observations of dermatoses made in MS clinics. The survey on the platform “REDCap” was designed to capture demographic information, symptoms, and history of Pso. All the information was then extracted and entered into the REDCap database along with relevant information on the history of skin conditions, signs and symptoms of dermatosis. Association between categorical variables were tested using Chi-square or Fisher's exact test. Continuous variables were compared between participants with and without Pso groups using independent-samples t-tests for normally distributed data, and Mann–Whitney U test for non-normally distributed data. The comparison of incidence of skin symptoms between with and without Pso groups was conducted using binary logistic regression reporting odds ratio (OR) and the associated 95% confidence interval (CI).
Results
A total of 204 patients were surveyed: 137 (67.2%) females and 67 (32.8%) males. The age of the patients ranged between 17 and 81 years with the mean age 48.8 years (SD = 13.6). The median Expanded Disability Status Scale (EDSS) score of the cohort was 1.5 (IQR: 0.75–2.50), with a disease duration of MS of 15 years (IQR: 10–21 years).
MS patients with Pso had a mean age of 50.8 years (SD: 13.7) and a median EDSS score of 1.5 (IQR: 0–3.9), with a disease duration of MS of 15 years (IQR: 9.25–19.50). In comparison, non-Pso MS patients had a mean age of 48.4 years (SD: 13.6) and a median EDSS score of 1.5 (IQR: 1.0–2.5), with a disease duration of MS of 15 years (IQR: 10–21; Table 1).
Table 1
| Characteristics | MS (n = 204) | MS without Pso (n = 176) | MS with Pso (n = 28) | p-value |
|---|---|---|---|---|
| Age (years), mean (+/- SD) | 48.8 (±13.6) | 48.4 (±13.6) | 50.8 (±13.7) | 0.40+ |
| Sex ratio (F:M) | 2.04:1 (67.2%: 32.8%) | 1.9:1 (65.3%: 34.7%) | 3.7:1 (78.6%: 21.4%) | 0.120++ |
| EDSS, median (IQR) | 1.5 (1.0–2.5) | 1.5 (1.0–2.5) | 1.5 (0.0–3.9) | 0.63+++ |
| Disease duration (years), median (IQR) | 15 (10–21) | 15 (10–21) | 15 (9.3–19.5) | 0.9+++ |
Demographics and clinical characteristics of MS cohort.
+ based on independent samples t-test, ++based on Fisher's exact-test, +++Mann-Whitney U test.
Due to loss to follow-up or transfer of care to another network, immunotherapy data is available for 196 out of 204 patients (Table 2). Of the total MS cohort, 57.2% were managed with B-cell therapies (ofatumumab and ocrelizumab). Among patients without Pso, 60.1% received B-cell therapies, whereas only 37% of those with Pso were treated with these agents. MS patients with Pso who receive B-cell therapy are more likely to be prescribed Kesimpta (ofatumumab) rather than Ocrevus (ocrelizumab) when compared to MS patients without Pso.
Table 2
| Disease Modifying Therapy | MS (n = 196) % | MS without Pso (n = 168) % | MS with Pso (n = 28) % |
|---|---|---|---|
| Nil | 4.1 | 2.4 | 14.3 |
| Ocrelizumab | 40.0 | 45.2 | 10.7 |
| Ofatumumab | 17.9 | 16.1 | 28.6 |
| Natalizumab | 17.4 | 17.2 | 17.9 |
| Dimethyl fumarate | 4.1 | 4.8 | 0 |
| Teriflunomide | 2.6 | 1.8 | 7.1 |
| BRACE | 0.5 | 0.6 | 3.6 |
| Alemtuzumab | 5.6 | 5.4 | 7.1 |
| Siponimod | 2.1 | 1.8 | 0 |
| Glatiramer acetate | 0.5 | 0.6 | 0 |
| Autologous stem cell transplant | 1.0 | 0.6 | 3.6 |
| Cladribine | 2.1 | 1.2 | 7.1 |
| Tolebrutinib | 0.5 | 0.6 | 0 |
Comparison of disease modifying therapy use in patients with and without Pso in the multiple sclerosis cohort.
The observed frequency of Pso in MS patients was 13.7% (28/204; 95% CI: 9.63–19.20%) as compared to an estimated 2.4% lifetime prevalence rate of physician-diagnosed Pso in the general Australian adult population (25).
In our study, of the 176 participants without a Pso diagnosis, various skin symptoms were reported including 6-month-history of intermittent irritation or erythematous rash (68/176, 38.6%), seasonal skin changes (69/176, 39.2%) and flaky, peeling, or scaly skin (35/176, 19.9%). Moreover, 54/176, 30.7% experienced dandruff; 21/176, 11.9% had thickened scaly skin behind ears and scalp; 25/176, 14.2% reported nail changes; and 24/176, 13.6% reported a family history of Pso. Interestingly, 9/28 or 32.1% of MS patients with Pso reported a concurrent diagnosis of eczema Table 3. Furthermore, except for new skin manifestations and dandruff, MS with Pso reported significantly higher odds of all other skin symptoms as compared with those without Pso (Odds ratio ranging between 2.01 and 22.14).
Table 3
| Skin manifestations | MS (n = 204) | MS without Pso (n = 176) | MS with Pso (n = 28) | OR (95% CI) | p-value |
|---|---|---|---|---|---|
| New skin manifestations since a diagnosis of MS | 66 (32.4%) | 53 (30.1%) | 13 (46.4%) | 2.01 (0.90–4.52) | 0.09 |
| 6-month-history of intermittent pruritus or erythematous rash | 176 (86.3%) | 68 (38.6%) | 22 (78.6%) | 5.82 (2.25–15.09) | < 0.001 |
| Seasonal skin changes | 82 (40.2%) | 69 (39.2%) | 13 (46.4%) | 2.93 (1.30–6.62) | 0.01 |
| Thickened scaly skin of extensors, behind ears or scalp | 42 (20.6%) | 21 (11.9%) | 21 (75.0%) | 22.14 (8.40–52.40) | < 0.001 |
| Flaky, peeling or scaly of skin | 55 (27.0%) | 35 (19.9%) | 20 (71.4%) | 10.07 (4.10–24.76) | < 0.001 |
| Dandruff | 63 (30.9%) | 54 (30.7%) | 9 (32.1%) | 1.07 (0.45–2.52) | 0.876 |
| Nail changes | 34 (16.7%) | 25 (14.2%) | 9 (32.1%) | 2.86 (1.16–7.03) | 0.022 |
| Diagnosis of eczema | 28 (13.7%) | 19 (10.8%) | 9 (32.1%) | 3.91 (1.55–9.87) | 0.004 |
Skin manifestations in MS patients.
Discussion
This study demonstrates that the frequency of Pso in MS patients treated in a tertiary clinic is six times greater (13.7% vs. 2.4%) than the Australian population (25). Previous studies have reported rates of between 0.4 and 7.7% (21, 22) and epidemiological data has consistently shown rates of Pso are high in MS.
In our study, MS patients with concurrent Pso showed a significantly higher frequency of skin symptoms, particularly those characteristics of Pso, including thickened scaly skin (OR: 22.14, p < 0.001) and flaky or peeling skin (OR: 10.07, p < 0.001). Intermittent rash or pruritus, seasonal skin changes, nail changes, and eczema were also significantly more common. Although new skin manifestations since MS diagnosis showed a non-significant trend (OR: 2.01, p = 0.09), the overall pattern supports the need for increased dermatological surveillance among MS patients.
While we observed differences in disease modifying therapy (DMT) use between patients with and without Pso, we cannot definitively conclude that Pso influenced DMT selection, as the timing of Pso onset relative to DMT initiation was not captured. This represents an important limitation of our analysis and should be interpreted with caution. Additional limitations include incomplete immunotherapy data for three patients due to loss of follow-up or transfer of care to different healthcare networks.
Interestingly, ocrelizumab use was lower among patients with Pso, which may reflect rising clinical awareness of Pso as a potential complication associated with this therapy. In contrast, ofatumumab, a more recently introduced anti-CD20 agent (approved in 2021, compared to 2018 for ocrelizumab) was more frequently used in the Pso group. This may be due to its more recent introduction and the relative lack of reported Pso cases at the time of treatment. The precise mechanism by which anti-CD20 therapy may trigger psoriasis in MS patients remains unclear. However, depletion of B cells may lead to dysregulation of T helper subsets, particularly Th1 and Th17, while the suppression of IL10-producing regulatory B cells (Bregs) may impair peripheral tolerance, thereby promoting psoriatic inflammation (26, 27).
On the other hand, cladribine and teriflunomide appeared to be more commonly used in patients with Pso, possibly reflecting the notion of the treating clinicians that these therapeutics are beneficial for psoriasis as well. Behrens et al. demonstrated that leflunomide was effective and safe in 514 European patients with psoriatic arthritis and another small study showed the efficacy of cladribine in psoriatic arthritis (28, 29).
Cendroswki and colleagues were the first to report an association in 1989 (30), and was followed by several population-based studies that reported a positive correlation between Pso and MS. A large single center, retrospective, cross-sectional study of 5,097 Pso patients and 1,829 MS patients in the US, found a significant association (OR = 1.521; 95% CI 1.01–2.29; P = 0.04) between the two conditions despite adjusting for potential confounders (31). A retrospective case-control study of 3,456 MS patients analyzing the association between Pso and MS disease activity and progression showed that 1.3% of patients with MS have Pso. Among these, 78% had Pso prior to MS diagnosis and the presence of Pso prior to the diagnosis of MS predicted a milder disease course and a longer interval to the second relapse (32). Three other small case-control studies reported higher frequencies of Pso in MS patients (33–35).
The presence of Pso prior to a diagnosis of MS has proven to be a risk factor for the disease. A Danish nationwide cohort study investigated the probability of developing MS in patients with mild (n = 58,628) or severe (n = 9,952) Pso and demonstrated significantly increased rates of MS in both groups compared to the reference population (36). The incidence of MS was highest among patients with severe Pso suggesting a disease severity-dependent increased risk of MS in Pso patients {mild Pso [incidence rate ratio (IRR), 1.84; 95% CI, 1.46–2.30] and severe Pso (IRR, 2.61; 95% CI, 1.44–4.74)} (36). Summary data including systematic reviews and meta-analyses support the association (11, 37). Dobson et al. found an overall increased risk for Pso in MS patients (OR = 1.31, 95% CI 1.09–1.57, P < 0.0001) (37). Interestingly, in this study the sex ratio of MS patients with Pso closely mirrored the known MS sex ratio (usually 3:1) rather than that of Pso (usually 1:1) (8, 38). This may also suggest shared immunogenetic pathogenesis among the two diseases and perhaps a particular MS/Pso phenotype.
The concomitance of Pso and MS may reflect shared genetic and environmental factors resulting in dysregulation of immune function. The prevalence of Pso and MS varies between geographical regions with both exhibiting a latitudinal gradient (greater prevalence toward the poles) and this has been shown to be partly explained by sun exposure and vitamin D levels (10, 39, 40). Additionally, infections along with lifestyle factors including smoking (both passive and active), diet, body mass index and stress have been proposed to impact the onset and progression of both diseases (41).
Pso and MS share other characteristics including heritability. Allelic variation in HLA-DRB1 and IL-12B are present in both diseases and genome wide screens reveal cross-over of many of the small contributory allelic variants that exert suspected effects on immune regulatory genes (11). Although the exact immunogenetic pathways for both diseases are unclear, activation of Th-1 and Th17 cells has been observed in both MS and Pso. In MS, inflammatory cytokines including interferon gamma; tumor necrosis factor alpha; and interleukins (IL)-17, 21, 22, and 26 have been implicated as primary pathogenic factors (42). These cytokines also play a key role in Pso (11).
IL-17 has been shown to be implicated in the pathogenesis of both Pso and MS (43). The immunologic role of IL-17 in Pso has been well established including IL-17 associated genes and an upregulation of IL-17A (44). IL-17A-targeting antibodies have been effectively prescribed for the treatment of Pso and yield promising outcomes in attenuating MS progression in an early-stage clinical trial (45). A high level of IL-17 was observed in perivascular cells isolated in the areas of active MS lesions suggesting the potential role of IL-17 in early stages of disease (46). This finding was in line with an animal study showing impressive clinical efficacy when anti-IL-17A was given to mice at the induction of experimental autoimmune encephalomyelitis (EAE). By contrast, mice lacking IL-17A were resistant to MS (47).
However, the immunological variance of these diseases cannot be over-simplified, and this is exemplified by the finding that some therapeutics will treat both diseases, whilst others will exacerbate the concomitant condition. Dimethyl fumarate is effective treatment for Pso and MS at least partly by downregulating the function of Th1 and Th17 T-lymphocytes (48, 49). Conversely, B-lymphocyte depletion and interferon beta treatment for MS can lead to exacerbation of Pso, while TNF-alpha blockade via monoclonal antibodies against the cytokine or it's receptor for psoriatic arthritis can exacerbate MS or induce de novo CNS demyelination (22, 50–52).
We are uncertain why the frequency of Pso is so high in our cohort and would expect similar rates among Caucasian populations. It may relate to data collection and the directed analysis of patients with questionnaires rather than based on population-based registries which may be prone to under-reporting or reduced data-capture. Alternatively, due to the unblinded nature of this observational cohort, the reporting from this series may be accentuated. Collectively, the rate of Pso is higher in MS patients, and this warrants further investigation to unearth common pathogenic mechanisms that may lead to better understanding of both diseases and precision treatments.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by the Royal North Shore Hospital Ethics Committee (Approval number: 2021/ETH00892). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
VM: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing, Project administration, Validation, Visualization. AF-V: Data curation, Investigation, Methodology, Validation, Visualization, Writing – review & editing. TM: Data curation, Investigation, Validation, Visualization, Writing – review & editing. OC: Data curation, Investigation, Methodology, Writing – review & editing. C-TK: Writing – review & editing, Formal analysis. HM: Supervision, Validation, Visualization, Writing – review & editing. VV: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing. GH: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – review & editing. SS: Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – review & editing, Formal analysis, Writing – original draft. JP: Conceptualization, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Gen AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2025.1663015/full#supplementary-material
References
1.
MontalbanXTintoreMSwantonJBarkhofFFazekasFFilippiMet al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology. (2010) 74:427–34. 10.1212/WNL.0b013e3181cec45c
2.
ThompsonAJBaranziniSEGeurtsJHemmerBCiccarelliO. Multiple sclerosis. Lancet. (2018) 391:1622–36. 10.1016/S0140-6736(18)30481-1
3.
Van LangelaarJRijversLSmoldersJVan LuijnMM. B and T cells driving multiple sclerosis: identity, mechanisms and potential triggers. Front Immunol. (2020) 11:760. 10.3389/fimmu.2020.00760
4.
ComiGBar-OrALassmannHUccelliAHartungHPMontalbanXet al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. (2021) 89:13–23. 10.1002/ana.25927
5.
MansillaMPresas-RodríguezSTeniente-SerraAGonzález-LarreateguiIQuirant-SánchezBFondelliFet al. Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy. Cell Mol Immunol. (2021) 18:1353–74. 10.1038/s41423-020-00618-z
6.
GonsetteR. Self-tolerance in multiple sclerosis. Acta Neurol Belg. (2012) 112:133–40. 10.1007/s13760-012-0061-x
7.
ProcacciniCDe RosaVPucinoVFormisanoLMatareseG. Animal models of multiple sclerosis. Eur J Pharmacol. (2015) 759:182–91. 10.1016/j.ejphar.2015.03.042
8.
FilippiMBar-OrAPiehlFPreziosaPSolariAVukusicSet al. Multiple sclerosis. Nat Rev Dis Primers. (2018) 4:43. 10.1038/s41572-018-0041-4
9.
KalincikTManouchehriniaASobisekLJokubaitisVSpelmanTHorakovaDet al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. (2017) 140:2426–43. 10.1093/brain/awx185
10.
ParisiRSymmonsDPGriffithsCEAshcroftDM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. (2013) 133:377–85. 10.1038/jid.2012.339
11.
LiuC-YTungT-HLeeC-YChangK-HWangS-HChiC-C. Association of multiple sclerosis with psoriasis: a systematic review and meta-analysis of observational studies. Am J Clin Dermatol. (2019) 20:201–8. 10.1007/s40257-018-0399-9
12.
ShapiroJCohenADWeitzmanDTalRDavidM. Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis. J Am Acad Dermatol. (2012) 66:252–8. 10.1016/j.jaad.2010.11.046
13.
KimballABGuerinALatremouille-ViauDAndrewPYGuptaSBaoYet al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med. (2010) 123:350–7. 10.1016/j.amjmed.2009.08.022
14.
ChiC-CWangJChenY-FWangS-HChenF-LTungT-H. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci. (2015) 78:232–8. 10.1016/j.jdermsci.2015.03.012
15.
ChiC-CTungT-HWangJLinY-SChenY-FHsuT-Ket al. Risk of uveitis among people with psoriasis: a nationwide cohort study. JAMA Ophthalmol. (2017) 135:415–22. 10.1001/jamaophthalmol.2017.0569
16.
AugustinMRadtkeMA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. (2014) 14:559–68. 10.1586/14737167.2014.914437
17.
GelfandJMTroxelABLewisJDKurdSKShinDBWangXet al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. (2007) 143:1493–9. 10.1001/archderm.143.12.1493
18.
ReichK. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. (2012) 26:3–11. 10.1111/j.1468-3083.2011.04410.x
19.
EdwardsLConstantinescuC. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler J. (2004) 10:575–81. 10.1191/1352458504ms1087oa
20.
BarcellosLFKamdarBBRamsayPPDeLoaCLincolnRRCaillierSet al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. (2006) 5:924–31. 10.1016/S1474-4422(06)70552-X
21.
MarrieRAReiderNCohenJStuveOSorensenPSCutterGet al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler J. (2015) 21:282–93. 10.1177/1352458514564490
22.
Silfvast-KaiserASHomanKBMansouriB. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis: Targets Ther. (2019) 9:81. 10.2147/PTT.S186637
23.
PatrickMTNairRPHeKStuartPEBilliACZhouXet al. Shared genetic risk factors for multiple sclerosis/psoriasis suggest involvement of interleukin-17 and Janus Kinase–signal transducers and activators of transcription signaling. Ann Neurol. (2023) 94:384–97. 10.1002/ana.26672
24.
Silfvast-KaiserASHomanKBMansouriB. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis: Targets Ther. 2019:81–90.
25.
ParisiRIskandarIYKontopantelisEAugustinMGriffithsCEAshcroftDM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020:369. 10.1136/bmj.m1590
26.
MontagueTLichtenbergICheungEKlineKMangkorntongsakulVKangYet al. Seronegative spondyloarthritis as a complication of anti-CD20 monoclonal antibody treatment in multiple sclerosis. Mult Scler Relat Disord. (2025) 99:106425. 10.1016/j.msard.2025.106425
27.
MizumakiKHoriiMKanoMKomuroAMatsushitaT. Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells. Sci Rep. (2021) 11:2106. 10.1038/s41598-021-81588-8
28.
BehrensFFinkenwirthCPavelkaKStolfaJSipek-DolnicarAThaçiDet al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res. (2013) 65:464–70. 10.1002/acr.21848
29.
EibschutzBBairdSMWeismanMHAmoxDGSpellmanMPiacquadioDet al. Oral 2-chlorodeoxyadenosine in psoriatic. Arthritis Rheum. (1995) 38:1604–9. 10.1002/art.1780381112
30.
CendrowskiW. Multiple sclerosis and psoriasis. Wiad Lek. (1989) 42:575–8.
31.
GuidoNCicesAIblerEHuynhTMajewskiSSableKet al. Multiple sclerosis association with psoriasis: a large US population, single centre, retrospective cross-sectional study. J Eur Acad Dermatol Venereol. (2017) 31:e397. 10.1111/jdv.14205
32.
MironGGurevichMBaumSAchironABarzilaiA. Psoriasis comorbidity affects multiple sclerosis neurological progression: a retrospective case–control analysis. J Eur Acad Dermatol Venereol. (2017) 31:2055–61. 10.1111/jdv.14403
33.
FellnerADanoMRegevKMosekAKarniA. Multiple sclerosis is associated with psoriasis. A case–control study. J Neurol Sci. (2014) 338:226–8. 10.1016/j.jns.2014.01.003
34.
HendersonRDBainCJPenderMP. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J Clin Neurosci. (2000) 7:434–7. 10.1054/jocn.2000.0693
35.
MidgardRGrønningMRiiseTKvåle4GNylandH. Multiple sclerosis and chronic inflammatory diseases a case-control study. Acta Neurol Scand. (1996) 93:322–8. 10.1111/j.1600-0404.1996.tb00004.x
36.
EgebergAMallbrisLGislasonGHSkovLHansenPR. Risk of multiple sclerosis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol. (2016) 136:93–8. 10.1038/JID.2015.350
37.
DobsonRGiovannoniG. Multiple sclerosis–a review. Eur J Neurol. (2019) 26:27–40. 10.1111/ene.13819
38.
ArmstrongAWBlauveltACallis DuffinKHuangY-HSavageLJGuoLet al. Psoriasis. Nat Rev Dis Primers. (2025) 11:45. 10.1038/s41572-025-00630-5
39.
MaroneyMHunterSF. Implications for multiple sclerosis in the era of the affordable care act: a clinical overview. Am J Manag Care. (2014) 20:S220–7.
40.
SimpsonSBlizzardLOtahalPVan der MeiITaylorB. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. (2011) 82:1132–41. 10.1136/jnnp.2011.240432
41.
AmatoMPDerfussTHemmerBLiblauRMontalbanXSoelberg SørensenPet al. Environmental modifiable risk factors for multiple sclerosis: report from the 2016 ECTRIMS focused workshop. Mult Scler J. (2018) 24:590–603. 10.1177/1352458516686847
42.
YadavSKMindurJEItoKDhib-JalbutS. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. (2015) 28:206–19. 10.1097/WCO.0000000000000205
43.
OmidianZAhmedRGiwaADonnerTHamadARA. IL-17 and limits of success. Cell Immunol. (2019) 339:33–40. 10.1016/j.cellimm.2018.09.001
44.
BlauveltAChiricozziA. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. (2018) 55:379–90. 10.1007/s12016-018-8702-3
45.
HavrdováEBelovaAGoloborodkoATisserantAWrightAWallstroemEet al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. (2016) 263:1287–95. 10.1007/s00415-016-8128-x
46.
TzartosJSFrieseMACranerMJPalaceJNewcombeJEsiriMMet al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. (2008) 172:146–55. 10.2353/ajpath.2008.070690
47.
McGinleyAMSuttonCEEdwardsSCLeaneCMDeCourceyJTeijeiroAet al. Interleukin-17A serves a priming role in autoimmunity by recruiting IL-1β-producing myeloid cells that promote pathogenic T cells. Immunity. (2020) 52:342–56. e6. 10.1016/j.immuni.2020.01.002
48.
XuZZhangFSunFGuKDongSHeD. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. (2015) 2015:CD011076. 10.1002/14651858.CD011076.pub2
49.
MrowietzUBarkerJBoehnckeWHIversenLKirbyBNaldiLet al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. (2018) 32:3–14. 10.1111/jdv.15218
50.
KwokTLooWJGuentherL. Psoriasis and multiple sclerosis: is there a link?J Cutan Med Surg. (2010) 14:151–5. 10.2310/7750.2010.09063
51.
La MantiaLCapsoniF. Psoriasis during interferon beta treatment for multiple sclerosis. Neurol Sci. (2010) 31:337–9. 10.1007/s10072-009-0184-x
52.
GränFKerstanASerflingEGoebelerMMuhammadK. Focus: skin: current developments in the immunology of psoriasis. Yale J Biol Med. (2020) 93:97.
Summary
Keywords
Australian population, multiple sclerosis, psoriasis, neuroimmunology, epidemiology study, autoimmune diseases
Citation
Mangkorntongsakul V, Fontes-Villalba A, Montague T, Charlton O, Kwong C-TJ, McGuire HM, Venkatesha V, Herkes G, Smith S and Parratt J (2025) The frequency of psoriasis in Australian multiple sclerosis patients. Front. Neurol. 16:1663015. doi: 10.3389/fneur.2025.1663015
Received
10 July 2025
Accepted
04 September 2025
Published
02 October 2025
Volume
16 - 2025
Edited by
Emanuele D'amico, University of Foggia, Italy
Reviewed by
Stephanie Dauth, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Allergology and Immunology, Germany
Ali Moghtaderi, Zahedan University of Medical Sciences, Iran
Updates
Copyright
© 2025 Mangkorntongsakul, Fontes-Villalba, Montague, Charlton, Kwong, McGuire, Venkatesha, Herkes, Smith and Parratt.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Varitsara Mangkorntongsakul vvaritsara@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.